Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma

Area of Science:

• Oncology
• Molecular Biology
• Cell Signaling

Background:

• The phosphatidylinositol-3-kinase (PI3K) pathway regulates vital cellular processes such as metabolism, proliferation, and survival.
• Aberrations in the PI3K pathway, including mutations and amplifications, are common in various cancers.
• Constitutive PI3K pathway activation confers a survival advantage and promotes resistance to therapy in malignancies like lymphomas.

Purpose of the Study:

• To review the current status of phosphatidylinositol-3-kinase (PI3K) pathway inhibitors in clinical development.
• To focus on the therapeutic potential of these inhibitors specifically for treating Hodgkin and non-Hodgkin lymphomas.

Main Methods:

• Literature review of clinical trials and preclinical studies.
• Analysis of data on PI3K pathway aberrations in lymphoid malignancies.
• Evaluation of the efficacy and safety of various PI3K inhibitors in lymphoma models.

Main Results:

• The PI3K pathway is frequently activated in Hodgkin and non-Hodgkin lymphomas, contributing to cancer progression.
• Numerous PI3K inhibitors targeting different pathway components are in various stages of clinical trials.
• These inhibitors show promise in preclinical models and early-phase clinical studies for lymphoma treatment.

Conclusions:

• Targeting the PI3K pathway represents a promising therapeutic strategy for lymphomas.
• Further clinical development of PI3K inhibitors is warranted to overcome treatment resistance and improve patient outcomes.
• Understanding PI3K pathway dysregulation is key to developing effective lymphoma therapies.